西酞普兰与万拉法新治疗抑郁症的循证药物经济学评价

Evidence-based evaluation on cost-effectiveness of citalopram and venlafaxine in the treatment of depressive disorder

目的评价西酞普兰与万拉法新治疗抑郁症的成本与效果。方法采用循证医学方法收集西酞普兰与万拉法新治疗抑郁症的临床资料,应用药物经济学的成本-效果分析法进行分析。结果西酞普兰与万拉法新治疗抑郁症的治愈率分别为41.11%、52.22%(P>0.05);成本-效果比分别为1425.13、2037.34。结论西酞普兰治疗抑郁症的成果-效果优于万拉法新。

Aim To evaluate the cost-effectiveness of citalopram and venlafaxine in the treatment of depressive disorders.Methods The clinical data of citalopram and venlafaxine in the treatment of depressive disorders were collected by evidence-based medicine method and were evaluated with cost-effectiveness analysis.Rusults The curative rates of citalopram and venlafaxine were 41.11% and 52.22%（P〉0.05）,respectively,and the corresponding cost-effectiveness ratios were 1425.13 and 2037.34.Conclusion The cost-effectiveness of citalopram is superior to venlafaxine in the treatment of depressive disorders.